摘要 |
<p>1427849 3 - Chloro - 2 - hydrazonomethyl- 4 - aza - 2,4 - pentadienenitriles BYK GULDEN LOMBERG CHEMISCHE FABRIK GmbH 5 Sept 1973 [8 Sept 1972 (3)] 41666/73 Heading C2C Novel compounds I in which R<SP>1</SP> and R<SP>2</SP> are a C 1-7 alkyl, C 2-7 alkenyl or C 2-7 alkynyl group or together represent C 2-5 alkylene (in which one or more methylene groups may be replaced by O, S, or NR<SP>7</SP>) R<SP>3</SP> is C(=X)R<SP>4</SP>, C(=X)-Y-R<SP>4</SP> or [in which R<SP>4</SP> is hydrogen, a C 1-14 alkyl, C 2-7 alkenyl or C 2-7 alkynyl group in which a methylene group may be replaced by oxygen and in which alkyl may be substituted by an NR<SP>5</SP>R<SP>6</SP> group, C 3-6 cycloalkyl optionally substituted by an NR<SP>5</SP>R<SP>6</SP> group or a phenyl or phenyl C 1-6 alkyl group (optionally substituted by C 1-4 alkyl, C 1-7 alkoxy, C 1-7 alkylthio, C 2-5 alkoxycarbonyl halogen, CF 3 , NO 2 and/or CN) R<SP>5</SP> and R<SP>6</SP> are hydrogen a C 1-7 alkyl, C 2-7 alkenyl or C 2-7 alkynyl group in which a methylene group may be replaced by oxygen, C 3-6 cycloalkyl or together represent C 2-5 alkylene in which one or more methylene groups may be replaced by O, S or NR<SP>7</SP>, X is O, S or NR<SP>7</SP>, Y is O, S or NH and R<SP>7</SP> is hydrogen, C 1-7 alkyl C 2-7 alkenyl or C 2-7 alkynyl C 2-7 alkenyl or C 2-7 alkynyl] and their salts are prepared by reaction of a compound II R<SP>1</SP>R<SP>2</SP>N-CH=N-C(Cl)=C(CN)-CHO with R<SP>3</SP>-NH-NH 2 . Compounds I prepared are those in which R<SP>1</SP> and R<SP>2</SP> are methyl and R 3 is (in which R<SP>4</SP> is hydrogen, C 1-14 alkyl in which a methylene group is optionally replaced by -O-, cyclohexyl, phenyl, p-methoxyphenyl, p-cyanophenyl or benzyl), -C(=Y)-NR<SP>5</SP>R<SP>6</SP> (in which R 5 and R 6 are hydrogen, methyl or phenyl and Y is O, S or NH). Compounds II are prepared by hydrolysis of in which R<SP>8</SP> and R<SP>9</SP> are defined as for R<SP>1</SP> and R<SP>2</SP> and Z is an anion. Compounds I inhibit xanthineoxidase and may also be used for treating coronary insufficiency and arrhythmias. They form with a suitable vehicle a pharmaceutical composition, which may be administered orally or parenterally.</p> |